Revisiting this post .
Still feel the same way .
Their TRV130 ( pain med ) program is FDA fast tracked.
They have funds to finish the trial. ...data due in March 2017
P2 data in 2015 " achieved primary endpoint with superior safety and tolerability profile ,compared to morphine "
Practically ignored now .
So yes ...still think its worth buying at these levels .